155 related articles for article (PubMed ID: 9007690)
1. A 3D QSAR CoMFA study of non-peptide angiotensin II receptor antagonists.
Belvisi L; Bravi G; Catalano G; Mabilia M; Salimbeni A; Scolastico C
J Comput Aided Mol Des; 1996 Dec; 10(6):567-82. PubMed ID: 9007690
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of nonpeptide angiotensin II receptor antagonists featuring acyclic imidazole-mimicking structural units.
Angiolini M; Belvisi L; Poma D; Salimbeni A; Sciammetta N; Scolastico C
Bioorg Med Chem; 1998 Nov; 6(11):2013-27. PubMed ID: 9881093
[TBL] [Abstract][Full Text] [Related]
3. Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor.
Prendergast K; Adams K; Greenlee WJ; Nachbar RB; Patchett AA; Underwood DJ
J Comput Aided Mol Des; 1994 Oct; 8(5):491-512. PubMed ID: 7876897
[TBL] [Abstract][Full Text] [Related]
4. The conformation and activity relationship of fused analogs of DuP753.
Yoo SE; Shin YA; Lee SH; Kim NJ
Bioorg Med Chem; 1995 Mar; 3(3):289-95. PubMed ID: 7606390
[TBL] [Abstract][Full Text] [Related]
5. A comparative molecular field analysis and molecular modelling studies on pyridylimidazole type of angiotensin II antagonists.
Yoo SE; Kim SK; Lee SH; Yi KY; Lee DW
Bioorg Med Chem; 1999 Dec; 7(12):2971-6. PubMed ID: 10658603
[TBL] [Abstract][Full Text] [Related]
6. Molecular modelling studies for the discovery of new substituted pyridines derivatives with angiotensin II AT1 receptor antagonists.
Sharma MC
Interdiscip Sci; 2014 Sep; 6(3):197-207. PubMed ID: 25205497
[TBL] [Abstract][Full Text] [Related]
7. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
Haddad G; Amiri F; Garcia R
Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.
Zhang J; Hao QQ; Liu X; Jing Z; Jia WQ; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Apr; 8(15):25612-25627. PubMed ID: 28445965
[TBL] [Abstract][Full Text] [Related]
9. Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity.
Lin HS; Rampersaud AA; Zimmerman K; Steinberg MI; Boyd DB
J Med Chem; 1992 Jul; 35(14):2658-67. PubMed ID: 1635064
[TBL] [Abstract][Full Text] [Related]
10. [Molecular biology of angiotensin II receptor and clinical application of the antagonist].
Hiwada K
Nihon Naika Gakkai Zasshi; 1994 Jan; 83(1):143-8. PubMed ID: 9132445
[No Abstract] [Full Text] [Related]
11. Angiotensin II receptor antagonism: losartan - sites and mechanisms of action.
Triggle DJ
Clin Ther; 1995; 17(6):1005-30. PubMed ID: 8750395
[TBL] [Abstract][Full Text] [Related]
12. Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR.
Li JS; Sharifi AM; Schiffrin EL
J Cardiovasc Pharmacol; 1997 Jul; 30(1):75-83. PubMed ID: 9268224
[TBL] [Abstract][Full Text] [Related]
13. Rationale for the chemical development of angiotensin II receptor antagonists.
Wexler RR; Carini DJ; Duncia JV; Johnson AL; Wells GJ; Chiu AT; Wong PC; Timmermans PB
Am J Hypertens; 1992 Dec; 5(12 Pt 2):209S-220S. PubMed ID: 1290616
[TBL] [Abstract][Full Text] [Related]
14. Nonpeptide angiotensin II receptor antagonists: in vivo inhibition of [125I-Sar1,Ile8]angiotensin II binding by losartan, EXP597 and L-159,282 in rats.
Wong PC; Herblin WF; Barbera FA; Bernard R; Bozarth TA; Watson CA; Gibson RE
Clin Exp Hypertens; 1996 Feb; 18(2):189-200. PubMed ID: 8869000
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of losartan (DuP 753)-induced angiotensin II receptor antagonism by PD123177 in rats.
Wong PC; Christ DD; Timmermans PB
Eur J Pharmacol; 1992 Sep; 220(2-3):267-70. PubMed ID: 1425998
[TBL] [Abstract][Full Text] [Related]
16. Understanding electrostatic and steric requirements related to hypertensive action of AT(1) antagonists using molecular modeling techniques.
da C Silva D; Maltarollo VG; de Lima EF; Weber KC; Honorio KM
J Mol Model; 2014 Jul; 20(7):2231. PubMed ID: 24935104
[TBL] [Abstract][Full Text] [Related]
17. [Losartan. The first non-peptide angiotensin II receptor antagonist for treatment of hypertension].
Ibsen H; Rasmussen S; Slatanach R
Ugeskr Laeger; 1996 Jun; 158(26):3798-802. PubMed ID: 8686080
[No Abstract] [Full Text] [Related]
18. Pharmacological characterization of KR-30988, a novel non-peptide AT1 receptor antagonist, in rat, rabbit and dog.
Lee BH; Lee SH; Jung YS; Seo HW; Yoo SE; Shin HS
J Pharm Pharmacol; 1999 Oct; 51(10):1191-200. PubMed ID: 10579691
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Berellini G; Cruciani G; Mannhold R
J Med Chem; 2005 Jun; 48(13):4389-99. PubMed ID: 15974591
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II and non-angiotensin II displaceable binding sites for [3H]losartan in the rat liver.
Grove KL; Speth RC
Biochem Pharmacol; 1993 Nov; 46(9):1653-60. PubMed ID: 8240422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
